Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) PT at $62.89
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten analysts that are covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price […]
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten analysts that are covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price […]
